Clinical trials recruiting for PDAC
11
Recruiting trials
34
US states with sites
13
Countries
27%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Nab-paclitaxel | 3 |
| daraxonrasib | 3 |
| Cetuximab | 2 |
| Gemcitabine | 2 |
| RMC-6236 | 2 |
| RMC-9805 | 2 |
| 5-Fluorouracil | 1 |
| Atebimetinib | 1 |
| Bevacizumab | 1 |
| GFH375 | 1 |
| Gemcitabine (GEM) | 1 |
| GnP | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Arizona | 6 |
| Florida | 6 |
| Maryland | 6 |
| Massachusetts | 6 |
| New York | 6 |
| Texas | 6 |
| Virginia | 6 |
| California | 4 |
| Colorado | 4 |
| Minnesota | 4 |
| North Carolina | 4 |
| Ohio | 4 |
Top cities
Boston, Massachusetts 6Fairfax, Virginia 6New York, New York 6Baltimore, Maryland 5Houston, Texas 4Nashville, Tennessee 4Rochester, Minnesota 4Salt Lake City, Utah 4Atlanta, Georgia 3Chicago, Illinois 3
Self-screener
Recruiting trials
- A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
- A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D Mutation
- Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Clinical Study of Lewis Antigen Assay Combined With CA19-9 Assay to Assess Prognosis in Patients With Pancreatic Cancer
- Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
- Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
Related conditions
Trials recruiting for PDAC often also study these conditions. Each links to its own recruiting-trial list.
Pancreatic cancer 870PDAC - Pancreatic Ductal Adenocarcinoma 21Pancreatic Ductal Adenocarcinoma (PDAC) 32Pancreatic Ductal Adenocarcinoma 64Pancreatic Cancer Metastatic 16Pancreatic Adenocarcinoma 49Pancreatic Adenocarcinoma Metastatic 6Colorectal cancer 1359Pancreatic Adenosquamous Carcinoma 4Non-small cell lung cancer 507
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for PDAC trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.